Desvenlafaxine in the treatment of major depressive disorder

@article{Pae2011DesvenlafaxineIT,
  title={Desvenlafaxine in the treatment of major depressive disorder},
  author={Chi-Un Pae},
  journal={Expert Opinion on Pharmacotherapy},
  year={2011},
  volume={12},
  pages={2923 - 2928}
}
  • C. Pae
  • Published 18 November 2011
  • Psychology, Biology
  • Expert Opinion on Pharmacotherapy
Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, large clinical trials demonstrating efficacy and safety for patients with MDD. Currently available data show that DESV has proven efficacy, acceptable safety and tolerability… 
A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder
TLDR
DESV was well tolerated and associated with improvement of depressive symptoms and may be a promising contender to treat depression in individuals on MMT and deserves further exploration in a randomized double-blinded clinical trial.
Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression.
  • C. Andrade
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2013
TLDR
Bupropion was added to venlafaxine in order to enhance antidepressant response through pharmacodynamic synergy, but rapid deterioration occurred rather than improvement: within days, Mr B became increasingly anxious, agitated, and restless; suicidal ideation emerged; and his blood pressure increased a week after the initiation of combination treatment.
Chapter 7 New Antidepressant Medication : Benefits Versus Adverse Effects
TLDR
The aim of this chapter is to review the literature, highlight the side effects of newer antidepressants, and especially point out themost important aspects of the latest agents approved for the treatment of major depressive disorder in adults: desvenlafaxine, levomilnacipran, vilazodone, and vortioxetine.
Desvenlafaxine succinate ameliorates visceral hypersensitivity but delays solid gastric emptying in rats.
TLDR
It is concluded that DVS reduces visceral sensitivity in a rodent model of visceral hypersensitivity and delays solid gastric emptying and should be made when DVS is used for treating patients.
Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs
  • J. Song, J. Yin, J. Chen
  • Biology, Psychology
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2013
TLDR
This study aimed at exploring possible effects of a serotonin‐norepinephrine reuptake inhibitor, desvenlafaxine succinate (DVS), on GI motility in dogs.
Which psychotropic medications induce hepatotoxicity?
Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors
TLDR
It is suggested that S-71031B is a more active enantiomer, and the differential pharmacokinetic profiles, but not target affinity, contribute to differences of S-071031 B and R-07 1031B in behavioral pharmacology.
Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs.
TLDR
DVS inhibits gastric contractions, slow waves, and accommodation in the fed state, and these inhibitory effects are associated with an increased sympathetic modulation in the gastrointestinal system.
Medications for alcohol use disorders: An overview
THE USE OF DESVENLAFAXINE IN THE THERAPY OF MAJOR DEPRESSION
A depressão configura-se em um transtorno de humor que incapacita os indivíduos de terem uma vida normal. Dentro das síndromes depressivas, a depressão maior é definida como a forma mais comum de
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
Desvenlafaxine: a new antidepressant or just another one?
  • C. Pae
  • Medicine, Psychology
    Expert opinion on pharmacotherapy
  • 2009
TLDR
Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on cytochrome P450 enzyme system and adverse event-prone neuroreceptors.
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder
TLDR
The results do not support the overall hypothesis that the serotonin-norepinephrine reuptake inhibitor desvenlafaxine has an efficacy advantage for the treatment of MDD in postmenopausal women because, in this particular subgroup, desven lafaxines failed to prove superiority over escitalopram.
The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment.
TLDR
To assess the pharmacokinetics, safety, and tolerability of desvenlafaxine in healthy volunteers vs. those with renal impairment, a single, oral, 100 mg dose was administered to subjects with mild, moderate, or severe renal impairment.
Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence
TLDR
DVS is a useful addition to the options available for the treatment of MDD in light of the limited efficacy of currently available antidepressants and its simple metabolism, lower risk of drug–drug interactions and lack of need for extensive titration to achieve therapeutic efficacy.
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
TLDR
These results demonstrate efficacy, safety, and tolerability of desvenlafaxine 50 mg/day for treating MDD and significant findings on secondary measures support the efficacy of desVENlafAXine 100 mg.
An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder
TLDR
Desvenlafaxine demonstrated short-term efficacy for treating major depressive disorder across the range of doses studied; a strong dose-response effect on tolerability was observed.
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician
TLDR
Overall results of two randomized, placebo-controlled, 8-week clinical trials demonstrated the efficacy of desvenlafaxine 50 mg/d for MDD, and findings were consistent with the SNRI class.
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder
TLDR
Analysis of the pooled data revealed that after 8 weeks of treatment, desvenlafaxine was significantly better than placebo on 17-item Hamilton Rating Scale for Depression and Clinical Global Impressions-Improvement item scores.
An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder
TLDR
Desvenlafaxine in the treatment of major depressive disorder exhibited a safety and tolerability profile generally consistent with the serotonin-norepinephrine reuptake inhibitor class.
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
TLDR
Desvenlafaxine is effective and well tolerated in the short-term treatment of MDD and the most commonly reported adverse events were nausea, insomnia, somnolence, dry mouth, dizziness, sweating, nervousness, anorexia, constipation, asthenia, and abnormal ejaculation/orgasm.
...
1
2
3
4
...